KZR
Kezar Life Sciences Inc
NASDAQ: KZR · HEALTHCARE · BIOTECHNOLOGY
$7.29
+0.00% today
Updated 2026-05-11
Market cap
$53.86M
P/E ratio
—
P/S ratio
6.03x
EPS (TTM)
$-7.66
Dividend yield
—
52W range
$4 – $8
Volume
0.1M
WallStSmart proprietary scores
33
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-1.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →211 stocks currently score above 75
Price targets
Analyst target
$6.00
-17.70%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy0 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.12x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -1.90 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-7.45M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $7.00M | $0.00 | $0.00 | — |
| Net income | $-65.32M | $-101.87M | $-83.74M | $-56.03M | $-5.76M |
| EPS | — | — | — | — | $-7.66 |
| Free cash flow | $-60.42M | $-83.45M | $-74.24M | $-51.78M | $-7.45M |
| Profit margin | — | -1,455.29% | — | — | — |
Peer comparison
Smart narrative
Kezar Life Sciences Inc trades at $7.29. Our Smart Value Score of 33/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -1.90, it sits in the distress.
Frequently asked questions
What is Kezar Life Sciences Inc's stock price?
Kezar Life Sciences Inc (KZR) trades at $7.29, on a P/S of 6.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Kezar Life Sciences Inc overvalued?
Kezar Life Sciences Inc carries a Smart Value Score of 33/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Kezar Life Sciences Inc (KZR)?
The 12-month analyst consensus target is $6.00, about 17.7% below the current $7.29. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Kezar Life Sciences Inc's Altman Z-Score is -1.90, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.03x
ROE-54.51%
Beta0.41
50D MA$7.12
200D MA$5.79
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—